From Significance of the study to Public health relevance:
Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.
Research findings to Therapeutic opportunity:
This study suggests, for the first time, that anti-hypertensive drug Torasemide, by regulating the expression of its target genes, it may increase the expression of tumor/metastasis suppressors BTG2 and INK4a/p16 (fig. 1).
Thereby, it may: (a) inhibit cell cycle progression; and (b) suppress migration, invasion and metastasis of cancer cells. [easy_payment currency=”USD”]
Thus, Torasemide may be prescribed for metastatic cancer patients to (i) increase the expression of metastasis suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy.
Taken together, this study suggests that oncologists may consider using the anti-metastatic property of Torasemide to stall the progression of advanced metastatic cancers.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D
Amount: $10#
Undisclosed mechanistic information: How Torasemide increases the expression of tumor/metastasis suppressors CCM3/KRIT1 and TIMP3
Fig1. Mechanistic insights into how the anti-hypertensive medication Torsemide functions as an anti-metastasis agent. Torasemide increases the expression of tumor/metastatic suppressors BTG2 and INK4a/p16 via up regulation of its target genes.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at info@genomediscovery.org
# Research cooperation
References:
Citation: Boominathan, L., Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastasis suppressors BTG2 and INK4a/p16, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 10/January/2017, 12.13 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org or newbioideas.com/
Courtesy: When you cite drop us a line at info@genomediscovery.org